Valiant Laborato

Has Valiant Laborato declared dividend?

No Dividend History Available

Who are the peers of the Valiant Laborato?

Valiant Laborato's peers include Jenburkt Pharma, Zim Laboratories, Medicamen Biotec, Albert David, Brooks Lab., Fredun Pharma, Oxygenta Pharma, Nectar Lifesci., and Infinium Pharma. Valiant Laborato has below-average management risk and a 1-year return of -15.29%, lower than its peers, with Oxygenta Pharma showing the highest return at 248.48%.

Peers: The peers of Valiant Laborato are Jenburkt Pharma, Zim Laboratories, Medicamen Biotec, Albert David, Brooks Lab., Fredun Pharma, Oxygenta Pharma, Nectar Lifesci., and Infinium Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Medicamen Biotec, Albert David, and the rest. Average management risk is found at Jenburkt Pharma, Zim Laboratories, Fredun Pharma, and the rest. Below Average management risk is noted at Valiant Laborato, Brooks Lab., and Nectar Lifesci. Growth is Excellent at Fredun Pharma, Below Average at Jenburkt Pharma, Zim Laboratories, Medicamen Biotec, Albert David, Valiant Laborato, Brooks Lab., Nectar Lifesci., and the rest. Capital Structure is Excellent at Medicamen Biotec, Albert David, Below Average at Valiant Laborato, Brooks Lab., Nectar Lifesci., and the rest, while Oxygenta Pharma does not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Oxygenta Pharma at 248.48%, while the peer with the lowest is Medicamen Biotec at -14.91%. Valiant Laborato's 1-year return is -15.29%, which is lower than both of these peers. Additionally, Medicamen Biotec, Albert David, Nectar Lifesci., and Brooks Lab. have negative six-month returns.

Who are in the management team of Valiant Laborato?

As of March 2022, the management team of Valiant Laborato includes Velji Gogri (Chairman), Santosh S. Vora (Managing Director), Shantilal Shivji Vora (Director), Paresh Shashikant Shah (Executive Director), Sonal A Vira (Independent Director), Sandeep Gupta (Additional Non-Executive Director), and Saloni Mehta (Company Secretary & Compliance Officer). Each member plays a key role in the company's governance and operations.

As of March 2022, the management team of Valiant Laborato includes the following members:<BR><BR>1. Velji Gogri - Chairman & Independent Director<BR>2. Santosh S. Vora - Managing Director<BR>3. Shantilal Shivji Vora - Director<BR>4. Paresh Shashikant Shah - Executive Director<BR>5. Sonal A Vira - Independent Director<BR>6. Sandeep Gupta - Additional Non-Executive Director<BR>7. Saloni Mehta - Company Secretary & Compliance Officer<BR><BR>Each member holds a significant position within the company, contributing to its governance and operational management.

What does Valiant Laborato do?

Valiant Laboratories Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology sector, formed in 1980 and converted to a Public Limited Company in 2021. As of March 2025, it reported net sales of 578 Cr and a net profit of 7 Cr, with a market cap of INR 509 Cr.

Overview: <BR>Valiant Laboratories Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History: <BR>Valiant Laboratories Ltd was originally formed as a Partnership Firm under the name M/s. Bharat Chemicals on October 17, 1980. It converted into a Public Limited Company on August 16, 2021. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 578 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 7 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 509 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.20 <BR>Return on Equity: -0.94% <BR>Price to Book: 2.14<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Who are the top shareholders of the Valiant Laborato?

The top shareholder of Valiant Laborato is Dhanvallabh Ventures LLP, holding 46.84%. Other notable shareholders include L7 Hitech Private Limited with 2.23% and individual investors collectively owning 16.28%.

The top shareholders of Valiant Laborato include Dhanvallabh Ventures LLP, which holds the largest stake at 46.84%. The company is primarily controlled by its promoters, and there are no pledged promoter holdings. In terms of public shareholders, L7 Hitech Private Limited is the highest with a holding of 2.23%. Additionally, individual investors collectively own 16.28% of the company. There are also three foreign institutional investors (FIIs) holding a total of 0.64%.

How big is Valiant Laborato?

As of 24th July, Valiant Laboratories Ltd has a market capitalization of 523.00 Cr and reported Net Sales of 133.38 Cr with a Net Profit loss of 2.20 Cr over the latest four quarters. The balance sheet for March 2024 shows Shareholder's Funds of 236.86 Cr and Total Assets of 342.69 Cr.

As of 24th July, Valiant Laboratories Ltd has a market capitalization of 523.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Valiant Laboratories reported Net Sales of 133.38 Cr. However, the company experienced a loss of 2.20 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 236.86 Cr and Total Assets of 342.69 Cr.

When is the next results date for Valiant Laborato?

Valiant Laborato will announce its results on August 8, 2025.

Valiant Laborato will declare its results on 08 August 2025.

Is Valiant Laborato technically bullish or bearish?

As of August 6, 2025, Valiant Laborato's trend is mildly bullish due to daily moving averages, but mixed signals from the weekly MACD and Bollinger Bands suggest caution despite a bullish weekly RSI.

As of 6 August 2025, the technical trend for Valiant Laborato has changed from sideways to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating a bullish signal. However, the weekly MACD remains bearish, and the Bollinger Bands are showing a mildly bearish trend on both weekly and monthly time frames. The weekly RSI is bullish, which supports the mildly bullish outlook, but the overall mixed signals from the MACD and Bollinger Bands suggest caution. The OBV is mildly bearish on the weekly but bullish on the monthly, indicating some divergence in volume trends. Overall, while there are bullish indicators, the strength is tempered by bearish signals in other areas.

Are Valiant Laborato latest results good or bad?

Valiant Laboratories' latest Q2 FY26 results are concerning, showing a 115.08% revenue growth but a drastic 89.01% decline in net profit, leading to severely low operating margins. Despite strong revenue, the company's profitability issues indicate significant operational challenges.

Valiant Laboratories' latest results for Q2 FY26 can be characterized as concerning. While the company reported a significant year-on-year revenue growth of 115.08%, the net profit for the quarter plummeted to ₹0.20 crores, reflecting a staggering 89.01% decline compared to the previous quarter. This sharp drop in profitability raises serious questions about the company's operational efficiency.<BR><BR>The operating margin has also deteriorated dramatically, falling to just 0.15% from 5.10% in the prior quarter, indicating severe operational stress. Furthermore, the company's PAT margin is a mere 0.43%, which is considered wafer-thin.<BR><BR>Despite the impressive revenue growth, the inability to convert this into meaningful profits suggests underlying issues with cost management and operational effectiveness. The stock has been under pressure, declining 27.79% over the past year, and the overall investment profile appears weak, with a quality grade of "Below Average" and a Mojo Score of only 23 out of 100.<BR><BR>In summary, while Valiant Laboratories has shown strong revenue growth, the significant decline in profitability and operational margins points to serious challenges, making the latest results more negative than positive.

How has been the historical performance of Valiant Laborato?

Valiant Laborato has experienced a significant decline in financial performance over the past three years, with net sales dropping from 333.91 Cr in March 2023 to 133.38 Cr in March 2025, and operating profit turning from a profit of 39.95 Cr to a loss of 4.68 Cr. Total liabilities increased substantially, indicating growing financial challenges.

Answer:<BR>The historical performance of Valiant Laborato shows a significant decline in key financial metrics over the past three years, particularly in net sales and profitability.<BR><BR>Breakdown:<BR>Valiant Laborato's net sales have decreased from 333.91 Cr in March 2023 to 182.06 Cr in March 2024, and further down to 133.38 Cr in March 2025. Total operating income followed a similar trend, dropping from 333.91 Cr in March 2023 to 133.38 Cr in March 2025. The company's operating profit (PBDIT) also saw a drastic decline, moving from a profit of 39.95 Cr in March 2023 to a loss of 4.68 Cr in March 2025. Consequently, profit before tax shifted from 38.14 Cr in March 2023 to a loss of 1.51 Cr in March 2025, and profit after tax fell from 29.00 Cr to a loss of 2.20 Cr in the same period. The company's total liabilities increased from 212.97 Cr in March 2023 to 400.86 Cr in March 2025, while total assets rose from 212.97 Cr to 400.86 Cr, indicating a growing financial burden. Cash flow from operating activities decreased significantly from 56.00 Cr in March 2023 to 1.00 Cr in March 2025, and the net cash outflow in March 2025 was recorded at -6.00 Cr, reflecting ongoing financial challenges.

Is Valiant Laborato overvalued or undervalued?

As of November 17, 2025, Valiant Laborato is considered overvalued with a PE ratio of 85.70 and an EV to EBITDA of 61.56, significantly higher than its peers like Sun Pharma and Cipla, and has underperformed the Sensex with a year-to-date return of -27.77%.

As of 17 November 2025, the valuation grade for Valiant Laborato has moved from attractive to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued, with a PE ratio of 85.70, an EV to EBITDA of 61.56, and a ROE of only 1.60%. These figures suggest that investors are paying a premium for earnings and cash flow, which may not be justified by the company's financial performance.<BR><BR>In comparison to its peers, Valiant Laborato's valuation metrics stand out significantly. For instance, Sun Pharma has a PE ratio of 36.69 and an EV to EBITDA of 24.22, while Cipla is valued more attractively with a PE of 22.81 and an EV to EBITDA of 16.14. The stark contrast in these ratios highlights that Valiant Laborato is trading at a much higher valuation relative to its industry counterparts. Additionally, the company's stock has underperformed the Sensex, with a year-to-date return of -27.77% compared to the Sensex's gain of 8.72%, reinforcing the notion that the stock may be overvalued in the current market environment.

Should I buy, sell or hold Valiant Laborato?

Why is Valiant Laboratories Ltd falling/rising?

As of 18-Jan, Valiant Laboratories Ltd's stock price is slightly rising at Rs 64.51, but it has significantly underperformed over the past year with a decline of -42.91%. Despite recent gains and increased investor participation, long-term fundamentals remain weak.

As of 18-Jan, Valiant Laboratories Ltd's stock price is experiencing a slight rise, currently at Rs 64.51, with a change of 0.06 (0.09%) upward. This increase can be attributed to a few positive factors despite the overall negative performance trends. The stock has outperformed its sector by 1.2% today and has shown consecutive gains over the last two days, rising by 0.42% during this period. Additionally, there has been a notable increase in investor participation, with a delivery volume of 37.95k on 14 January, which is up by 21.41% compared to the 5-day average.<BR><BR>However, it is important to note that the stock has been underperforming in the long term, with a significant decline of -42.91% over the past year, while the Sensex has increased by 8.47% during the same period. The company has also demonstrated weak long-term fundamental strength, with a -49.92% CAGR growth in operating profits over the last five years and a low return on equity of 0.80%. Despite declaring positive results for the last three consecutive quarters, the overall sentiment remains cautious due to these underlying weaknesses. <BR><BR>In summary, while Valiant Laboratories Ltd is currently seeing a minor rise in its stock price, this is juxtaposed against a backdrop of significant long-term declines and fundamental challenges.

Which are the latest news on Valiant Laborato?